NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.78 +0.76 (+0.97%) GOLD FUTURES
2,392.10 +32.20 (+1.36%) DOW
39,845.11 +287.00 (+0.73%) Bitcoin GBP
51,724.19 +3,272.58 (+6.75%)
NVO Jan 2025 87.500 call
| Previous close | 47.90 |
| Open | 47.90 |
| Bid | 50.00 |
| Ask | 51.75 |
| Strike | 87.50 |
| Expiry date | 2025-01-17 |
| Day's range | 47.90 - 47.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 835 |
BenzingaNo Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Novo Nordisk A/S (NYSE:NVO) says that despite earlier warnings from the Danish Medicines Agency about potential shortages of Wegovy, it does not anticipate a shortage of its weight-loss drug in Denmark. The agency had warned of limited supply for the 1 mg injection pen from late May to mid-June and the 0.5 mg injection pen from mid-June to mid-July due to increased demand. Also Read: What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Q
BenzingaEli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, which contains tirzepatide. As part of the deal, Totality Medispa will pay Lilly a monetary payment and cease using Lilly’s branding to promote its products. In addition to the financial settlement, Totality Medispa is required to take corrective actions, including ensuring that any compounded tirzepatid
ZacksShould You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
